Jeffrey Epstein, a science philanthropist, praises the FDA's approval of a melanoma inhibitor cocktail. Epstein has donated to the Melanoma Research Alliance, which funds research on inhibitor drugs. The FDA approved a combination of Dabrafenib and trametinib for melanoma patients with BRAF mutations. Epstein emphasizes the need for more combination drugs to be approved quickly.
documents/EFTA00584434.pdf
{}